头颈部鳞状细胞癌的免疫疗法
Immunotherapy in Head and Neck Squamous Cell Cancer.
作者信息
Denaro Nerina, Merlano Marco Carlo
机构信息
Department of Oncology, ASO Santa Croce e Carle, Cuneo, Italy.
出版信息
Clin Exp Otorhinolaryngol. 2018 Dec;11(4):217-223. doi: 10.21053/ceo.2018.00150. Epub 2018 Jul 6.
Abstract
Prognosis in relapsed metastatic head and neck squamous cell cancer (RM-HNSCC) is dismal. Platinum based chemotherapy in combination with Cetuximab is used in first-line setting, while no further validated options are available at progression. Immunotherapy has produced durable clinical benefit in some patients with RM-HNSCC although the premises are several patients are nonresponders. Studies are ongoing to determine predictive factors and the ideal setting/combination of novel immunotherapies. In this paper, we discuss the past and present of immunotherapy in head and neck cancer and provide an up-to-date information regarding the potential ways to improve immunotherapy outcomes in HNSCC.
摘要
复发转移性头颈部鳞状细胞癌（RM-HNSCC）的预后很差。铂类化疗联合西妥昔单抗用于一线治疗，而疾病进展时没有进一步经过验证的治疗方案。免疫疗法已在一些RM-HNSCC患者中产生了持久的临床获益，尽管有几个前提条件是部分患者无反应。目前正在进行研究以确定预测因素以及新型免疫疗法的理想应用环境/联合方案。在本文中，我们讨论了头颈癌免疫疗法的过去和现在，并提供了有关改善HNSCC免疫治疗结果潜在方法的最新信息。
相似文献
1
Immunotherapy in Head and Neck Squamous Cell Cancer.头颈部鳞状细胞癌的免疫疗法
Clin Exp Otorhinolaryngol. 2018 Dec;11(4):217-223. doi: 10.21053/ceo.2018.00150. Epub 2018 Jul 6.
2
Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.免疫疗法在复发性和转移性头颈部鳞状细胞癌患者中的应用。
Anticancer Agents Med Chem. 2019;19(3):290-303. doi: 10.2174/1871520618666180910092356.
3
Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.含西妥昔单抗的联合方案用于局部晚期及复发或转移性头颈部鳞状细胞癌
Front Oncol. 2019 May 20;9:383. doi: 10.3389/fonc.2019.00383. eCollection 2019.
4
Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.功能基因组学揭示了头颈部鳞状细胞癌患者对西妥昔单抗反应性的生物学机制。
Clin Cancer Res. 2016 Aug 1;22(15):3961-70. doi: 10.1158/1078-0432.CCR-15-2547. Epub 2016 Feb 26.
5
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.美国食品药品监督管理局批准摘要：帕博利珠单抗用于治疗在含铂化疗期间或之后出现疾病进展的复发性或转移性头颈部鳞状细胞癌。
Oncologist. 2017 Jul;22(7):873-878. doi: 10.1634/theoncologist.2016-0496. Epub 2017 May 22.
6
The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches.免疫疗法在头颈部鳞状细胞癌中的前景：联合免疫疗法策略
ESMO Open. 2017 Feb 13;1(6):e000122. doi: 10.1136/esmoopen-2016-000122. eCollection 2016.
7
Immunotherapy for recurrent/metastatic head and neck cancer.复发性/转移性头颈癌的免疫治疗
Curr Opin Otolaryngol Head Neck Surg. 2018 Apr;26(2):152-156. doi: 10.1097/MOO.0000000000000448.
8
Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.头颈部鳞状细胞癌的免疫肿瘤学：临床试验新进展、新兴预测因素和未满足的需求。
Cancer Treat Rev. 2018 Apr;65:78-86. doi: 10.1016/j.ctrv.2018.03.003. Epub 2018 Mar 20.
9
The promise of immunotherapy in head and neck squamous cell carcinoma.免疫疗法在头颈部鳞状细胞癌中的应用前景。
Ann Oncol. 2016 Sep;27(9):1675-85. doi: 10.1093/annonc/mdw226. Epub 2016 Jul 5.
10
Immunotherapeutic Approaches to Head and Neck Cancer.头颈部癌的免疫治疗方法
Crit Rev Oncog. 2018;23(3-4):161-171. doi: 10.1615/CritRevOncog.2018027641.
引用本文的文献
1
Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN.头颈部鳞状细胞癌中标准化PD-L1和肿瘤浸润淋巴细胞评分的一致性、相关性及临床影响
Cancers (Basel). 2022 May 14;14(10):2431. doi: 10.3390/cancers14102431.
2
Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients.头颈部鳞状细胞癌患者肿瘤微环境的高度多重数字空间分析
Front Oncol. 2021 Jan 19;10:607349. doi: 10.3389/fonc.2020.607349. eCollection 2020.
3
Prospects and Opportunities for Microsystems and Microfluidic Devices in the Field of Otorhinolaryngology.微系统和微流控设备在耳鼻咽喉科领域的前景与机遇
Clin Exp Otorhinolaryngol. 2021 Feb;14(1):29-42. doi: 10.21053/ceo.2020.00626. Epub 2020 Aug 11.
4
Inhibition of Glutaredoxin 5 predisposes Cisplatin-resistant Head and Neck Cancer Cells to Ferroptosis.谷氧还蛋白 5 的抑制使顺铂耐药的头颈部癌细胞容易发生铁死亡。
Theranostics. 2020 Jun 19;10(17):7775-7786. doi: 10.7150/thno.46903. eCollection 2020.
5
Ex vivo culture of head and neck cancer explants in cell sheet for testing chemotherapeutic sensitivity.头颈部肿瘤外植体的细胞片层体外培养用于测试化疗敏感性。
J Cancer Res Clin Oncol. 2020 Oct;146(10):2497-2507. doi: 10.1007/s00432-020-03306-7. Epub 2020 Jul 3.
6
How I treat squamous ENT cancer.我如何治疗耳鼻喉科鳞状细胞癌。
ESMO Open. 2019 Jul 16;4(Suppl 2):e000542. doi: 10.1136/esmoopen-2019-000542. eCollection 2019.
7
Metastatic lymph node burden predictive of survival in patients undergoing primary surgery for laryngeal and hypopharyngeal cancer.转移性淋巴结负担可预测喉和下咽癌患者行根治性手术的生存情况。
J Cancer Res Clin Oncol. 2019 Oct;145(10):2565-2572. doi: 10.1007/s00432-019-02990-4. Epub 2019 Jul 27.
8
Lymph node ratio predictive of recurrence, distant metastasis, and survival in submandibular gland carcinoma patients.颈淋巴结比率可预测颌下腺癌患者的复发、远处转移和生存。
J Cancer Res Clin Oncol. 2019 Apr;145(4):1055-1062. doi: 10.1007/s00432-019-02876-5. Epub 2019 Feb 26.
本文引用的文献
1
Emerging targets in cancer immunotherapy.癌症免疫疗法中的新兴靶点。
Semin Cancer Biol. 2018 Oct;52(Pt 2):39-52. doi: 10.1016/j.semcancer.2017.10.001. Epub 2017 Oct 5.
2
PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4 TILs in the Presence of PD-L1 TAMs.头颈部鳞状细胞癌中PD-1的表达主要源于在存在PD-L1肿瘤相关巨噬细胞的情况下功能失能的CD4肿瘤浸润淋巴细胞。
Cancer Res. 2017 Nov 15;77(22):6365-6374. doi: 10.1158/0008-5472.CAN-16-3453. Epub 2017 Sep 25.
3
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的总生存期
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
4
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.程序性死亡受体配体1：头颈部鳞状细胞癌中的一种新型预后生物标志物
Oncotarget. 2017 May 2;8(32):52889-52900. doi: 10.18632/oncotarget.17547. eCollection 2017 Aug 8.
5
Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma.肿瘤相关巨噬细胞和调节性 T 细胞在 EBV 阳性和 EBV 阴性鼻咽癌中的预后作用。
J Clin Pathol. 2018 Mar;71(3):267-274. doi: 10.1136/jclinpath-2017-204664. Epub 2017 Sep 6.
6
The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches.免疫疗法在头颈部鳞状细胞癌中的前景：联合免疫疗法策略
ESMO Open. 2017 Feb 13;1(6):e000122. doi: 10.1136/esmoopen-2016-000122. eCollection 2016.
7
Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy.人乳头瘤病毒驱动的免疫偏离：免疫治疗面临的挑战与新机遇
Ther Adv Vaccines. 2017 Jun;5(3):69-82. doi: 10.1177/2051013617717914. Epub 2017 Jul 5.
8
Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.迈向免疫检查点抑制剂精准放疗之路
Clin Cancer Res. 2018 Jan 15;24(2):259-265. doi: 10.1158/1078-0432.CCR-16-0037. Epub 2017 Jul 27.
9
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.纳武利尤单抗对比研究者选择的标准单药疗法用于复发性或转移性头颈部鳞状细胞癌（CheckMate 141）：一项随机3期试验的健康相关生活质量结果
Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.
10
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.肿瘤中 PD-L2 的表达：与癌症抗 PD-1 治疗的相关性。
Clin Cancer Res. 2017 Jun 15;23(12):3158-3167. doi: 10.1158/1078-0432.CCR-16-1761.
Zotero 插件